SPRO vs WFC · P/E 9.6, rev $48.0M vs P/E 15, $272.05B cap
Spero Therapeutics Inc (SPRO) versus Wells Fargo & Company (WFC) — a side-by-side from cached financials, not a winner call.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Wells Fargo & Company (WFC) is a banks - diversified company listed on US. It is led by Charlie Scharf.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
WFC does not have a complete income-statement cache yet.
SPRO currently screens at market cap $149.5M and trailing P/E 9.6. WFC currently screens at market cap $272.05B and trailing P/E 15.0.
Not investment advice. Open the SPRO and WFC stock pages for the full models.
Not investment advice.